FDA Concerns Over PI3K Inhibitors Snag MEI Pharma, Kyowa Kirin

Shares of MEI Pharma, Inc. plunged nearly 50% in premarket trading after the company announced that additional clinical research will be needed in order for the company’s phosphatidylinositol-3-kinase (PI3K) inhibitor zandelisib to be considered for regulatory approval.